Ultime notizie per FS KKR Capital (NYSE:FSK) Azioni

FS KKR Capital

FS KKR Capital Corp is a business development company based in the United States. Its portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies. It is focused on providing customized credit solutions to private upper middle-market companies, which it generally defines as companies with annual EBITDA of at least $50 million at the time of investment.

FS KKR Capital Corp

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

News

Price Target

Reiteration

Analyst Ratings

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

WIIM

TDUP

ThredUp shares are trading higher after the company reported better-than-expected Q3 EPS and sales and slightly raised its FY2024 sales guidance.

Deutsche Bank analyst Brian Bedell maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Hold and lowers the price target from $20 to $19.

Deutsche Bank Maintains Hold on Franklin Resources, Lowers Price Target to $19

Deutsche Bank analyst Brian Bedell maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $51 to $56.

Deutsche Bank Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $56

EGHT

8x8 shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

Deutsche Bank analyst Brian Bedell maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Buy and lowers the price target from $219 to $204.

Deutsche Bank Maintains Buy on Affiliated Managers Group, Lowers Price Target to $204

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) with a Buy and maintains $70 price target.

IRON

HC Wainwright & Co. Reiterates Buy on Disc Medicine, Maintains $70 Price Target

Trio Petroleum Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPET#NASDAQ">TPET</a>) shares are trading lower by 19% to 10 cents Tuesday morning after the company announced a <a href="https://www.benzinga.com/pressreleases/24/11/g41727117/trio-petroleum-corp-announces-reverse-stock-split">1-for-20 reverse stock split</a>, approved by its board and shareholders, to take effect on November 14. 
What To Know: This split will consolidate every 20 shares of common stock into 1 share, affecting all outstanding shares equally. Stockholders' ownership percentages will remain the same, though fractional shares will be rounded up. 
Adjustments will also be made to Trio's equity awards. The stock will begin trading on a post-split basis on November 15, under the same symbol (TPET) with a new CUSIP number.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TPET has a 52-week high of $0.72 and a 52-week low of $0.08.

TPET

Why Trio Petroleum (TPET) Stock Is Trading Lower

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Atossa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) with a Buy and maintains $6 price target.

ATOS

HC Wainwright & Co. Reiterates Buy on Atossa Therapeutics, Maintains $6 Price Target

Trio Petroleum shares are trading lower after the company announced a 1-for-20 reverse stock split.

<ul>
<li>DJT</li>
<li>PLTR</li>
<li>SMCI</li>
<li>LOT</li>
<li>TSLA</li>
<li>NVDA</li>
<li>HIMS</li>
<li>AI</li>
<li>LINE</li>
<li>BA</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

Hims & Hers Health, Inc. Class A Common Stock

HIMS

LINE

NVDA

PLTR

SMCI

TSLA

Top 10 Trending Stocks On WallStreetBets As Of November 5, 2024 (Via Swaggy Stocks)

Biotech

General

LYEL

Lyell To Present Initial Clinical Data From Phase 1-2 Trial Of IMPT-314 CAR T-Cell Therapy For B-Cell Lymphoma At ASH 2024, Highlighting Fast Track Designation And Dual-Targeting CD19/CD20 Approach

Barclays analyst Alex Scott maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Equal-Weight and raises the price target from C$76 to C$79.

TSX:SLF

Barclays Maintains Equal-Weight on Sun Life Financial, Raises Price Target to C$79

Bionomics Ltd &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) shares are trading higher by 177% to 53 cents Tuesday morning after the company announced it <a href="https://www.benzinga.com/pressreleases/24/11/g41727839/bionomics-receives-milestone-payment-of-aus-1m-from-carina-biotech-for-bnc101-partnered-legacy-onc">received a milestone payment</a> of AUD$1 million from Carina Biotech related to their partnered oncology program, BNC101.
What To Know: This payment aligns with their 2020 exclusive license agreement for BNC101, a monoclonal antibody targeting LGR5, a cancer stem cell antigen. 
Carina Biotech is developing an LGR5-targeted CAR-T therapy, CNA3103, for metastatic colorectal cancer, and Bionomics could earn up to AUD$118 million in further development, regulatory and commercial milestone payments if the therapy is fully developed and marketed.
Additionally, Bionomics is set to earn royalties on net sales and may receive a share of sublicensing revenue. Bionomics' CEO highlighted this payment as a testament to their research strength and noted the progress of their strategic partnership with Merck for an Alzheimer&#8217;s therapy, which could soon yield additional milestone payments.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41740288/us-stocks-set-for-cautious-start-as-investors-brace-for-volatility-on-election-day-expert-points-to">US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To &#8216;Pretty Well Overall&#8217; Historical Performance</a>
<h2 class="wp-block-heading">How To Buy BNOX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Bionomics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BNOX has a 52-week high of $2.84 and a 52-week low of $0.18.

BNOX

Why Bionomics (BNOX) Stock Is Up 100% Today

REQORSA Modulates In Vivo Immune Responses Against Cancers
AUSTIN, Texas, Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294293-1&amp;h=152405195&amp;u=https%3A%2F%2Fwww.genprex.com%2F&amp;a=Genprex%2C+Inc.">Genprex, Inc.</a> ("Genprex" or the "Company") (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gnpx#NASDAQ">GNPX</a>), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at Meharry Medical College will present a poster detailing positive preclinical data from a study of the Company's lead drug candidate, Reqorsa&#xAE; Gene Therapy (quaratusugene ozeplasmid)&nbsp;evaluating TUSC2's role in modulating immune responses in cancer. The poster will be presented at the 39th Annual Society for Immunotherapy of Cancer Meeting being held November 6-10, 2024 in Houston, Texas.

Penny Stocks

GNPX

Genprex Collaborators Present Preclinical Data On Reqorsa Gene Therapy At The Society For Immunotherapy Of Cancer 2024 Annual Meeting; REQORSA Modulates In Vivo Immune Responses Against Cancers

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 5.75% on an annualized basis producing an average annual return of 18.82%. Currently, Brinker International has a market capitalization of $4.85 billion. 
Buying $1000 In EAT: If an investor had bought $1000 of EAT stock 5 years ago, it would be worth $2,342.45 today based on a price of $108.40 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817033_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today

CRKN

Crown Suspends Equity Line of Credit Agreement With Liqueous LP

Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) has outperformed the market over the past 15 years by 2.58% on an annualized basis producing an average annual return of 14.16%. Currently, Union Pacific has a market capitalization of $139.38 billion. 
Buying $100 In UNP: If an investor had bought $100 of UNP stock 15 years ago, it would be worth $740.21 today based on a price of $229.91 for UNP at the time of writing.
<h3>Union Pacific's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730817028_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth $700 Today

Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) ("Nuwellis" or the "Company"), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the "Existing Warrants") to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms.
Ladenburg Thalmann &amp; Co. Inc. acted as the exclusive warrant inducement agent for the exercise of the Existing Warrants.
In consideration for the immediate exercise of the Existing Warrants, the Company will issue Series I common stock purchase warrants (the "Series I Warrants") and Series II common stock purchase warrants (the "Series II Warrants") to purchase up to an aggregate of 3,665,034 shares of common stock. The Series I Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of five (5) years from the date of exercisability. The Series II Warrants will have an exercise price of $1.94, will be exercisable six (6) months from the date of issuance, and will have a term of two (2) years from the date of exercisability. The Series I Warrants and Series II Warrants are fixed priced and do not contain any variable pricing features.
The Series I Warrants and Series II Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933 (the "Securities Act"), and, along with the shares of common stock issuable upon their exercise, have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements.&nbsp; The securities were offered only to accredited investors. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the Series I Warrants and Series II Warrants.

Offerings

NUWE

Nuwellis Announces Exercise Of Warrants For $5.1M Of Gross Proceeds

Barclays analyst Brandt Montour maintains Wynn Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) with a Overweight and lowers the price target from $125 to $119.

WYNN

Barclays Maintains Overweight on Wynn Resorts, Lowers Price Target to $119

Good News For BDCs

FS KKR Capital ( ($FSK) ) has shared an announcement. FS KKR Capital Corp. has declared a generous fourth-quarter cash distribution of $0.70 per sh...

FS KKR Capital Announces Q4 Cash Distribution and Upcoming Conference Call

FS KKR Capital declares $0.64 dividend & $0.06 supplemental dividend

Invest In All Weather BDC Dividend Portfolio

The Ultimate Portfolio Structure For Stress-Free High Current Income

My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 12 Buys

Wells Fargo Remains a Buy on FS KKR Capital (FSK)

J.P. Morgan analyst Melissa Wedel maintained a Hold rating on FS KKR Capital (FSK – Research Report) yesterday and set a price target of $19.50. Th...

J.P. Morgan Remains a Hold on FS KKR Capital (FSK)

FS KKR Capital: Quality BDC, But I'm Not Buying

FS KKR: 15.91% Discount To NAV, Yields Around 14%, And One Of My Favorite BDCs

AAPL

ABBV

AGNC

ALIZF

APLE

ARCC

AVGO

BABA

BASFY

BAYZF

BIZD

BMWYY

BXSL

CBAUF

CION

CSCO

CSWC

FDUS

FSNUF

GAIN

GBDC

GILD

GLAD

GMRE

GOOD

GSBD

HTGC

INTC

MAIN

MFIC

MSDL

MSFT

NEWT

OBDC

PBDC

PFLT

RITM

SEMHF

SHEL

STAG

STWD

UNIT

VONOY

Press Releases

FSK Completes Public Offering of $400 million 7.875% Unsecured Notes Due 2029

FSK Announces Earnings Release and Conference Call Schedule for Fourth Quarter and Full Year 2023

Earnings

Dividends

FS KKR Capital Corp. Announces Fourth Quarter and Full Year 2023 Results

FSK Announces Earnings Release and Conference Call Schedule for First Quarter 2024

FS KKR Capital Corp. Announces First Quarter 2024 Results

FSK Prices Public Offering of $600 million 6.875% Unsecured Notes Due 2029

FSK Completes Public Offering of $600 million 6.875% Unsecured Notes Due 2029

FSK Announces Earnings Release and Conference Call Schedule for Second Quarter 2024

FS KKR Capital Corp. Announces Second Quarter 2024 Results

FSK Announces Earnings Release and Conference Call Schedule for Third Quarter 2024; Declares Fourth Quarter 2024 Distribution of $0.70 per share

Comments

FS KKR Capital

Notizie

Ultime notizie per FS KKR Capital (NYSE:FSK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO